Induction, consolidation, and maintenance study design (blinatumomab group).^aIn induction cycle 1 week 1, 9 µg per day, and 28 µg per day thereafter by continuous infusion. ^bObserved cycle 3 day 1 varied between day 85 and day 131 on study. ^cObserved maintenance day 1 varied between day 211 and day 266 on study. ^dMaintenance therapy was discontinued in the case of transition to HSCT, investigator discretion, toxicity, relapse, or use of protocol-excluded medications.